Short Interest in Lifevantage Corporation (NASDAQ:LFVN) Expands By 32.2%

Lifevantage Corporation (NASDAQ:LFVN) was the recipient of a significant increase in short interest in January. As of January 30th, there was short interest totaling 3,664,089 shares, an increase of 32.2% from the January 15th total of 2,771,966 shares. Currently, 36.7% of the shares of the stock are short sold. Based on an average trading volume of 280,426 shares, the days-to-cover ratio is currently 13.1 days. Based on an average trading volume of 280,426 shares, the days-to-cover ratio is currently 13.1 days. Currently, 36.7% of the shares of the stock are short sold.

Lifevantage Stock Up 2.2%

LFVN stock opened at $5.03 on Monday. The firm has a market cap of $64.33 million, a price-to-earnings ratio of 8.38 and a beta of 0.33. The company’s fifty day simple moving average is $5.97 and its 200 day simple moving average is $8.53. Lifevantage has a 12-month low of $3.90 and a 12-month high of $19.28.

Lifevantage (NASDAQ:LFVN) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $0.15 earnings per share for the quarter, missing the consensus estimate of $0.22 by ($0.07). Lifevantage had a return on equity of 29.59% and a net margin of 3.74%.The business had revenue of $48.93 million during the quarter, compared to the consensus estimate of $54.40 million. Lifevantage has set its FY 2026 guidance at 0.600-0.800 EPS.

Lifevantage Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, March 16th. Shareholders of record on Monday, March 2nd will be paid a dividend of $0.045 per share. The ex-dividend date is Monday, March 2nd. This represents a $0.18 dividend on an annualized basis and a yield of 3.6%. Lifevantage’s payout ratio is 30.00%.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Loop Capital set a $5.00 price target on shares of Lifevantage in a report on Thursday, February 5th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Lifevantage in a report on Monday, December 29th. Lake Street Capital reissued a “buy” rating on shares of Lifevantage in a research note on Thursday, February 5th. Finally, Wall Street Zen downgraded Lifevantage from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. One investment analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $5.00.

Insider Activity at Lifevantage

In other news, Director Michael A. Beindorff sold 12,607 shares of the firm’s stock in a transaction that occurred on Wednesday, November 19th. The shares were sold at an average price of $6.42, for a total value of $80,936.94. Following the sale, the director directly owned 43,806 shares in the company, valued at approximately $281,234.52. This trade represents a 22.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 21.95% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Police & Firemen s Retirement System of New Jersey purchased a new stake in Lifevantage in the 2nd quarter valued at $31,000. JPMorgan Chase & Co. grew its stake in shares of Lifevantage by 870.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 5,016 shares of the company’s stock worth $66,000 after acquiring an additional 4,499 shares in the last quarter. Franklin Resources Inc. purchased a new stake in shares of Lifevantage in the fourth quarter valued at about $74,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Lifevantage in the 2nd quarter worth approximately $76,000. Finally, Aristides Capital LLC bought a new position in shares of Lifevantage in the fourth quarter valued at approximately $76,000. Hedge funds and other institutional investors own 35.32% of the company’s stock.

About Lifevantage

LifeVantage Corporation is a publicly traded company that develops, markets and distributes nutritional supplements, skincare products and weight-management solutions through a direct-selling business model. The company’s flagship offering, Protandim®, is formulated to activate the Nrf2 pathway, which is associated with cellular defense processes. LifeVantage also markets the PhysIQ® line for metabolism and body composition support and the TrueScience® skincare regimen, targeting a range of health and wellness needs.

Founded in 1999 and headquartered in Sandy, Utah, LifeVantage combines research in nutrigenomics with a network of independent distributors to bring its products to market.